- The key vendors in the Global Pompe Disease Market 2015-2019 are Amicus Therapeutics Inc., BioMarin Pharmaceutical Inc. and Genzyme Corp
London, 31 March 2015: TechNavio, an independent tech-focused global research firm, has announced the publication of its market research report on the Global Pompe Disease Market 2015-2019. Increased awareness has made regulatory authorities work steadily toward developing guidelines and providing assistance to drug manufacturers to promote R&D of drugs to treat the disease. Emerging economies are rapidly becoming aware of the importance of orphan drug designations and are working toward the development of regulatory protocols required to award these designations. The Global Pompe Disease market is growing rapidly and is expected to post a CAGR of 11.79 percent during the forecast period of 2014-2019.
The Global Pompe Disease market is growing rapidly because of the presence of unmet medical needs, special provisions allocated for orphan drugs, designation under ICD-10 code, and the low advertising cost of the disease.
“Organizations such as the United Pompe Foundation, International Pompe Association, Canadian Association of Pompe, Acid Maltase Deficiency Association, and NORD are involved in promoting various events online and offline to spread awareness,” says Faisal Ghaus, Vice President of Technavio Research.
“Various events and fund raising programs are being organized by government and non-government organizations to raise awareness and educate people about the disease and its diagnosis and treatment options resulting in social and economic benefits and improvement in patients’ quality of life.”
To define the market conditions in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
